16-17 March 2020, Clare College, University of Cambridge, UK
COST Action: CA18233 - European Network for Innovative Diagnosis and Treatment of Chronic Neutropenias
Meeting Title: 2nd Management Committee and 1st Working Groups Meeting
Location: Clare College, University of Cambridge, UK, [ clareconferencing.com ]
Meeting Dates:16-17 March 2020
Important information about EuNET-INNOCHRON activities in the context of Coronavirus outbreak
Due to the evolving situation and uncertainty regarding the coronavirus (COVID-19) outbreak, the #COST Association has taken the decision to suspend the COST physical meetings: https://www.cost.eu/who-we-are/about-cost/coronavirus-covid-19/
By thinking ahead, the EuNet-INNOCHRON Action Chairs, the Local Organizers, the Grant Holder and the Management Committee (MC) had already planned a Video-Tele conference approach for Monday's meeting. Therefore, the MC and WG Meetings will take place as a one-day event as already announced.We are looking forward to seeing you “on line” on Monday 16 and having interesting presentations and fruitful discussions.
All times below are according to UK time zone. (GMT). Please adjust for your local time zone accordingly.
Agenda
EuNET-INNOCHRON members can find the Meeting presentations here.
08:00 – 10:00 Management Committee Meeting [To join by phone: 0044 1223 761376. PIN: 623907]
10:00 – 10:30 Break
10:30- 11:30 Working Group 1 ‘Congenital Neutropenias’ session [To join by phone: 0044 1223 761376. PIN: 459377]
- Genetic heterogeneity of congenital neutropenias. K. Welte
- Molecular basis of Shwachman-Diamond syndrome. A. Warren
- Genomic profiling and characterization of novel variants in glycogen storage disease type Ib: from the NGS method to the CRISPR/Cas9 technology. A. Skakic & S. Pavlovic
- Development of nonsense mutation suppression therapies for BM failure syndromes. V. Bezzerri
11:30 – 12.30 Working Group 2 ‘Acquired Neutropenias’ session
- How we investigate neutropenia within EuNet-INNOCHRON (survey results). J. Palmblad
- Antibody-mediated neutropenias. The challenges in anti-neutrophil antibody screening. P. Hӧglund
- Non-antibody mediated neutropenias.
NGS-based immunoprofiling of T-cell mediated neutropenias. K. Stamatopoulos
How can distinguish benign and neutropenias preceding MDS. H. Papadaki
12:30 – 13:30 Lunch
13:30 – 14:30 Working Group 3 ‘Mechanisms of Leukaemic Evolution’ session [To join by phone: 0044 1223 761376. PIN: 874350]
- Role of the promyelocyte leukemia (PML) protein in SCN. P. Olofsen
- Leukemic progression of SCN in a mouse model: Identification of a driver mutation in CXXC4. I.Touw.
- The role of genetic/chromosome abnormalities in malignancies derived from BM failures and other leukemia predisposition syndromes. C. Mecucci.
14:30 – 15:30 Guidelines session
Areas in EuNet-INNOCHRON where evidence-based guidelines, consensus based guidelines, and position documents are needed. C.Dufour, F. Fioredda, F. Cerisoli, J. Palmblad and all
15:30 – 16:30 Working Group 4 ‘Targets for Novel Therapies’ session
- Establishment of the patients-specific cell-based platform for drug development in Congenital Neutropenia. J.Skokowa
- Potential of inhibitors of neutrophil elastase for treatment of ELANE-associated Congenital Neutropenia. J. Cichy
- In vivo zebrafish model of congenital neutropenia for drug screening. B. Bajoghli
- Novel small molecule in the treatment of SDS patients. A.Warren
16:30 – 17:00 Break
17:00 – 18:00 Working Group 5 ‘Registries and biobanking’ session
- Registries for chronic neutropenia in EU: present situation. J.Donadieu
- Organization of a registry: Hanover SCNIR experience. C.Zeidler
- Organization of a registry: French experience. J.Donadieu
- Biobank: Needs and organization. K. Stamatopoulos
18:00 – 18:30 The role of SME Companies in EuNet-INNOCHRON.
SafeBlood BioAnalytica SA. Dr D. CHRISTOU
X4 Pharmaceuticals. Dr S. Cohen
18:30 - 19:00 Summary and conclusions H. Papadaki, C. Dufour, A. Warren
Speaker |
Affiliation |
||
Dr |
Baubak Bajoghli |
University Hospital Tübingen, Tübingen, Germany |
|
Dr |
Valentino Bezzerri |
Cystic Fibrosis Center, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona,Italy |
|
Dr |
Francesco Cerisoli, |
Coordinator Research & Development, European Hematology Association |
|
Dr |
Dimitrios Christou |
SafeBlood BioAnalytica SA, Athens, Greece |
|
Prof |
Joanna Cichy |
Jagiellonin University, Krakow, Poland |
|
Dr |
Sarah Cohen |
X4 Pharmaceuticals GmbH, Vienna, Austria |
|
Dr |
Jean Donadieu |
AP-HP, Trousseau Hospital, France, Paris |
|
Dr |
Carlo Dufour |
G.Gaslini Children's Research Hospital, Hematology Unit, Genova, Italy |
|
Dr |
Francesca Fioredda |
G.Gaslini Children's Research Hospital, Genova, Italy |
|
Prof |
Petter Hӧglund |
Karolinska University Hospital, Stockholm, Sweden |
|
Prof |
Cristina Mecucci |
University of Perugia, Perugia, Italy |
|
Ms |
Patricia Olofsen |
Erasmus MC, Rotterdam, Netherlands |
|
Prof |
Jan Palmblad |
Karolinska Institutet, Stockholm, Sweden |
|
Prof |
Helen Papadaki |
University of Crete, School of Medicine / University Hospital of Heraklion, Crete, Greece |
|
Dr |
Sonja Pavlovic |
Institute of Molecular Genetics and Genetic Engineering University of Belgrade, Belgrade, Serbia |
|
Dr |
Anita Skakic |
Institute of Molecular Genetics and Genetic Engineering University of Belgrade, Belgrade, Serbia |
|
Prof |
Julia Skokowa |
University Hospital Tübingen, Tübingen, Germany |
|
Dr |
Kostas Stamatopoulos |
Institute of Applied Biosciences, Thessaloniki, Greece |
|
Prof |
Ivo Touw |
Erasmus MC, Rotterdam, Netherlands |
|
Prof |
Alan Warren |
University of Cambridge, Cambridge, United Kingdom |
|
Prof |
Karl Welte |
University Children Hospital, Tübingen, Germany |
|
Dr |
Cornelia Zeidler |
Hannover Medical School/ Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover, Germany |
|